Friday, July 29, 2011

Amgen's Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion

Second Quarter 2011 Product Sales Increased 8 Percent to $3.9 Billion

Second Quarter 2011 Adjusted and GAAP Earnings Per Share (EPS) Were $1.37 and $1.25, Respectively

Amgen Announced its First Quarterly Cash Dividend of $0.28 Per Share

2011 Total Revenue and Adjusted EPS Guidance Updated to Upper End of $15.1 Billion to $15.5 Billion and $5.00 to $5.20, Respectively

THOUSAND OAKS, Calif., July 29, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) reported total revenue increased 4 percent during the second quarter of 2011 to $3,959 million versus $3,804 million in the second quarter of 2010. Total product sales increased 8 percent in the second quarter of 2011 to $3,893 million versus $3,613 million in the second quarter of 2010. The increase in total revenue in the second quarter of 2011 included a decline in other revenue due to certain milestone payments earned in the second quarter of 2010.

Read the rest of this entry

Posted in Press Releases

Monday, July 25, 2011

Amgen Announces Webcast of 2011 Second Quarter Financial Results

THOUSAND OAKS, Calif., July 25, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today announced that it will report its second quarter financial results on Friday, July 29, 2011 before the opening of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 8 a.m.  Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen’s senior management team.

Read the rest of this entry

Posted in Press Releases

Friday, July 15, 2011

Amgen Resolves G-CSF Patent Litigation With Teva

Teva Admits Neutroval(TM) Infringes Amgen’s Valid and Enforceable Patents

Court Enters Permanent Injunction

THOUSAND OAKS, Calif., July 15, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) announced today that the United States (U.S.) District Court in Pennsylvania has entered final judgment and a permanent injunction against Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA prohibiting them from infringing Amgen’s patents relating to human G-CSF (granulocyte colony-stimulating factor) and methods for its use. Today’s judgment was accompanied by Teva’s admission that its Neutroval(TM) product infringes the two Amgen patents at issue in the litigation and that those patents are valid and enforceable. The Court’s injunction extends until Nov.  10, 2013, after which date Teva may sell Neutroval in the U.S. Regarding Neugranin(TM), another Teva G-CSF product, Teva agrees not to sell Neugranin until Nov. 10, 2013 unless it first obtains a final court decision that Amgen’s patents are not infringed by Neugranin. Pursuant to the parties’ agreement, the launch date for either product could be sooner if certain unexpected events occur: a third party launches a similar G-CSF product and Amgen fails to sue that third party, or the patents are held invalid or unenforceable in a final court decision in an action brought by a third party.  The settlement terms do not include any financial payments between the parties.  The two patents at issue in the litigation, U.S. Patent Nos. 5,580,755 and 5,582,823, expire in early December 2013.

Read the rest of this entry

Posted in Press Releases

Friday, July 15, 2011

XGEVA® (Denosumab) Granted Marketing Authorization in the European Union

Additional Year of Market Exclusivity Granted Based on Significant Clinical Benefit XGEVA Provides Over Existing Therapies

THOUSAND OAKS, Calif., July 15, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has granted marketing authorization for XGEVA® (denosumab) for the prevention of skeletal-related events (SREs) (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors. This approval of XGEVA applies to all 27 European Union (EU) member states. The EC also granted XGEVA an additional year of data and market exclusivity in the EU since the indication was considered new for denosumab and based on the significant clinical benefit of XGEVA in comparison with existing therapies.

Read the rest of this entry

Posted in Press Releases

Tuesday, July 05, 2011

Amgen and UCB Team Up With NASA on Final Space Shuttle Mission to Conduct Preclinical Test of Sclerostin Antibody on Bone Loss

Thousand Oaks, Calif. and BRUSSELS, July 5, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) announced today that they are collaborating with the National Aeronautics and Space Administration (NASA) Ames Research Center to conduct a preclinical test of a sclerostin antibody in an experiment that will take place aboard space shuttle Atlantis, on the final NASA shuttle mission, Space Shuttle Flight STS-135, scheduled to launch July 8, 2011.

Read the rest of this entry

Posted in Press Releases